BRAF and thyroid gland carcinoma: Statistical analysis of the LFC profiles with the BRAF V600E-specific inhibitor dabrafenib differentiated BRAF V600E and non-BRAF V600E thyroid cancers, with six peptides (BAD_93- 105, CD27_212-224, MPIP1_172-184, PRKDC_2618-2630, and RB_242-254) showing p < 0.05.